CA2107476C - Pharmaceutical packaging unit containing plasminogen activators for multiple bolus administration - Google Patents

Pharmaceutical packaging unit containing plasminogen activators for multiple bolus administration Download PDF

Info

Publication number
CA2107476C
CA2107476C CA002107476A CA2107476A CA2107476C CA 2107476 C CA2107476 C CA 2107476C CA 002107476 A CA002107476 A CA 002107476A CA 2107476 A CA2107476 A CA 2107476A CA 2107476 C CA2107476 C CA 2107476C
Authority
CA
Canada
Prior art keywords
plasminogen activator
bolus
administration
packaging unit
plasminogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002107476A
Other languages
English (en)
French (fr)
Other versions
CA2107476A1 (en
Inventor
Martin Ulrich
Reinhard Koenig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25902885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2107476(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19914123845 external-priority patent/DE4123845A1/de
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of CA2107476A1 publication Critical patent/CA2107476A1/en
Application granted granted Critical
Publication of CA2107476C publication Critical patent/CA2107476C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002107476A 1991-04-16 1992-04-15 Pharmaceutical packaging unit containing plasminogen activators for multiple bolus administration Expired - Lifetime CA2107476C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4112398 1991-04-16
DEP4112398.0 1991-04-16
DE19914123845 DE4123845A1 (de) 1991-07-18 1991-07-18 Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
DEP4123845.1 1991-07-18
PCT/EP1992/000851 WO1992018157A1 (de) 1991-04-16 1992-04-15 Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe

Publications (2)

Publication Number Publication Date
CA2107476A1 CA2107476A1 (en) 1992-10-17
CA2107476C true CA2107476C (en) 2007-12-18

Family

ID=25902885

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002107476A Expired - Lifetime CA2107476C (en) 1991-04-16 1992-04-15 Pharmaceutical packaging unit containing plasminogen activators for multiple bolus administration

Country Status (11)

Country Link
US (3) US5500411A (Direct)
EP (2) EP0580685B1 (Direct)
JP (1) JPH06506459A (Direct)
AT (1) ATE132373T1 (Direct)
CA (1) CA2107476C (Direct)
DE (1) DE59204945D1 (Direct)
DK (1) DK0580685T3 (Direct)
ES (1) ES2082465T3 (Direct)
GR (1) GR3018740T3 (Direct)
HK (1) HK117096A (Direct)
WO (1) WO1992018157A1 (Direct)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580685B1 (de) * 1991-04-16 1996-01-03 Roche Diagnostics GmbH Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
US5510330A (en) † 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
AU3765897A (en) * 1996-08-14 1998-03-06 Jurgen Brodersen Gram Use of a plasminogen activator for the treatment of pulmonary disorders
JP4155561B2 (ja) * 2000-12-26 2008-09-24 国立大学法人佐賀大学 アレルギー性疾患検査方法
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US20100260669A1 (en) * 2004-05-13 2010-10-14 Anthony Joonkyoo Yun Treatment of Seasonal Conditions Through Modulation of the Autonomic Nervous System
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
US8309063B2 (en) * 2005-06-10 2012-11-13 Amcol International Corporation Stable sunscreen compositions containing zinc oxide
TWI482628B (zh) * 2007-10-18 2015-05-01 Lundbeck & Co As H 新穎之血栓溶解病患次群
CN119948064A (zh) * 2022-09-23 2025-05-06 庄伟哲 靶向整合素 αIIbβ3的含组织纤维溶酶原活化剂或其变异体的融合蛋白质及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8508717D0 (en) * 1985-04-03 1985-05-09 Beecham Group Plc Composition
US5234686A (en) * 1985-04-03 1993-08-10 Beecham Group P.L.C. Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH02504102A (ja) * 1987-06-30 1990-11-29 ジェネンテク，インコーポレイテッド 血管障害治療のための改良法
US4935237A (en) * 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
GB8814604D0 (en) * 1988-06-20 1988-07-27 Wellcome Found Medicaments
IE69054B1 (en) * 1988-07-20 1996-08-07 Schering Ag Vampire bat salivary plasminogen activators
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants
EP0580685B1 (de) * 1991-04-16 1996-01-03 Roche Diagnostics GmbH Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe

Also Published As

Publication number Publication date
US6235279B1 (en) 2001-05-22
GR3018740T3 (en) 1996-04-30
JPH06506459A (ja) 1994-07-21
EP0709096A2 (de) 1996-05-01
HK117096A (en) 1996-07-12
EP0580685A1 (de) 1994-02-02
DK0580685T3 (da) 1996-03-04
EP0709096A3 (Direct) 1996-05-08
CA2107476A1 (en) 1992-10-17
US5500411A (en) 1996-03-19
ATE132373T1 (de) 1996-01-15
DE59204945D1 (de) 1996-02-15
WO1992018157A1 (de) 1992-10-29
EP0580685B1 (de) 1996-01-03
ES2082465T3 (es) 1996-03-16
US5690931A (en) 1997-11-25

Similar Documents

Publication Publication Date Title
Neuhaus et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator
CA2107476C (en) Pharmaceutical packaging unit containing plasminogen activators for multiple bolus administration
Magnani Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction
EP0751785B2 (en) Combinations of thrombolytically active proteins and anticoagulants, and uses thereof
Yao et al. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
IE64462B1 (en) Thrombosis treatment with fibrinolytics and prostacyclins
Yasuda et al. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis
US4944943A (en) Mixture of a substance having thrombolytic activity and of an antithrombotic substance
Rapold et al. Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator
EP0181267B1 (en) Fibrinolysis-enhancing agents
Saitoh et al. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
CA1297010C (en) Combination of t-pa and a prostaglandin
Dupe et al. Acylated derivatives of streptokinase-plasminogen activator complex as thrombolytic agents in a dog model of aged venous thrombosis
Martin et al. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis
IL106981A (en) Use of active-direct thrombin monitoring for the production of medical products that have thrombolytic activity
JPS6150927B2 (Direct)
US5336495A (en) Use of staphylokinase for the preparation of a pharmaceutical composition for treating arterial thromboisi
CN107536844A (zh) 烟酰胺单核苷酸在制备预防或治疗rtPA血管并发症的药物中的应用
EP0700298B1 (en) Therapeutic use of hemoglobin in the treatment of blood vessel blockage
WO1992022202A1 (en) Thrombolytic and perfluorochemical treatment for myocardial infraction
US4790988A (en) Method and compositions for the treatment of thrombotic episodes
Cade Thrombolytic therapy
Schneider Taprostene, a stable prostacyclin analogue, enhances the thrombolytic efficacy of saruplase (recombinant single-chain urokinase-type plasminogen activator) in rabbits with pulmonary embolized thrombi
Bisteni et al. Effectiveness of nupercaine hydrochloride and phenobarbital sodium in the suppression of ventricular tachycardia associated with acute myocardial infarction
Yao et al. Receptors Enhances Thrombolysis and Delays Reocclusion in Canine Coronary Arteries

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry